A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
Terminated · Phase 3 · NCT05074433
Conditions: Immunocompromised
At a glance
- Research payments reported, 2025
- $43,922
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 66
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- casirivimab+imdevimab (drug), Placebo (drug)
- Dates
- Started 2021-10-25; completion 2022-05-18
- Results posted
- Yes
The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants. The secondary objectives of the study are: * To evaluate the safety and tolerability of repeated SC injections of casirivimab+imdevimab in the study population * To characterize concentrations of casirivimab and imdevimab in serum over time * To assess the immunogenicity of casirivimab and imdevimab
From ClinicalTrials.gov, last updated 2025-10-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $43,922 in research payments for this study in 2025 (50 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Fred Hutchinson Cancer Research Center $43,922
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.